Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids

Free Radical Biology and Medicine

Volumn 28, Issue 1, 2000, Pages 129-140

  Jolivalt, Corinne ^a   Leininger Muller, Brigitte ^a   Bertrand, Philippe ^a   Herber, Régine ^a   Christen, Yves ^b   Siest, Gérard ^a  

^a Centre du Medicament URA CNRS 597   (France)

^b IPSEN   (France)

Author keywords

Alzheimer's disease; Apolipoprotein E; Free radicals; Myeloperoxidase; Oxidation; Phospholipids; Thrombin proteolysis

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; FREE RADICAL; ISOPROTEIN; MYELOPEROXIDASE; PHOSPHOLIPID; THROMBIN;

ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOBLOTTING; LIPID OXIDATION; OXIDATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SENILE PLAQUE;

ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MEMBRANE LIPIDS; OXIDATION-REDUCTION; PEROXIDASE; PHOSPHOLIPIDS; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; THROMBIN;

EID: 0033954735     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00232-4     Document Type: Article

References (57)

1. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
2. Frölich L., Riederer P. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug. Res. 45:1995;443-446.
3. Berlett B.S., Stadtman E.R. Protein oxidation in aging, disease and oxidative stress. J. Biol. Chem. 272:1997;20313-20316.
4. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., Markesbery W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 88:1991;10540-10543.
5. Carney J.M., Carney A.M. Role of protein oxidation in aging and in age-associated neurodegenerative diseases. Life Sci. 55:1994;2097-2103.
6. Mahley R.W. Apolipoprotein E cholesterol transport protein with expanding role in cell biology . Science. 240:1988;622-630.
7. Poirier J. Apolipoprotein E in animal models of brain injury and in Alzheimer's disease. Trends Neurosci. 12:1994;525-530.
8. Siest, G.; Pillot, T.; Régis-Bailly, A.; Leininger Muller, B.; Steinmetz, J.; Galteau, M. M.; Visvikis, S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem. 41:1068-086; 1995.
9. West H.L., Rebeck G.W., Hyman B.T. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci. Lett. 175:1994;46-48.
10. Strittmatter W.J., Saunders A., Schmechel D., Pericakvance M., Englhild J., Salvesen O.S., Roses A.D. Apolipoprotein E high affinity binding β-amyloid and increased frequency of type 4 allele in late onset Alzheimer's disease . Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
11. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L., Jakes R., Huang D.Y., Pericak-Vance M., Schmechel D., Roses A.D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau implications for Alzheimer's disease . Proc. Natl. Acad. Sci. USA. 91:1994;11183-11186.
12. Weisgraber K.H. Apolipoprotein E structure-function relationships . Adv. Protein Chem. 45:1994;249-302.
13. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol. Brain Res. 33:1995;174-178.
14. Davies K.J.A. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J. Biol. Chem. 262:1987;9895-9901.
15. Castano E.M., Prelli F., Pras M., Frangione B. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J. Biol. Chem. 270:1995;17610-17615.
16. Marques M.A., Tolar M., Harmony J.A.K., Crutcher K.A. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport. 7:1996;2529-2532.
17. Leininger Muller B., Jolivalt C., Bertrand P., Siest G. Oxidation of human apolipoprotein E and cerebral enzymatic systems. Alzheimer's Rep. 1:1998;95-99.
18. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide relevance to Alzheimer's disease . Proc. Natl. Acad. Soc. USA. 91:1994;3270-3274.
19. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Genet. 14:1996;55-61.
20. Montine T.J., Huang D.Y., Valentine W.M., Amarnath V., Saunders A., Weisgraber K.H., Graham D.G., Strittmatter W.J. Crosslinking of apolipoprotein E by products of lipid peroxidation. J. Neuropathol. Exp. Neurol. 55:1996;202-210.
21. Hunt J.V., Bailey J.R., Schultz D.L., McKay A.G., Michinson M.J. Apolipoprotein oxidation in the absence of lipid peroxidation enhances LDL uptake by macrophage. FEBS Lett. 349:1994;375-379.
22. Noguchi N., Gotoh N., Niki E. Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals. Biochim. Biophys. Acta. 1213:1994;176-182.
23. Reinheckel T., Nedelev B., Prause J., Augustin W., Schulz H.U., Lippert H., Halangk W. Occurrence of oxidatively modified proteins an early event in experimental acute pancreatitis . Free Radic. Biol. Med. 24:1998;393-400.
24. Jerlich A., Fabjan J.S., Tschabushing S., Smirnova A.V., Horakova L., Hayn M., Auer H., Guttenberger H., Leis H.J., Tatzber F., Waeg G., Schaur R.J. Human low density lipoprotein as a target of hypochloride generated by myeloperoxidase. Free Radic. Biol. Med. 24:1998;1139-1148.
25. Leininger Muller, B.; Jolivalt, C.; Pillot, T.; Lagrange, P.; Livertoux, M. H.; Grassiot, M. C.; Minn, A.; Siest, G. . Apolipoprotein E and Alzheimer's disease. In: Roses A. D.; Weisgraber K. H.; Christen Y., eds. Research and perspectives in Alzheimer's disease. Paris: Springer-Verlag; 1995: 161-69.
26. Drozdz R., Naskalski J.W. Action of myeloperoxidase-hydrogen peroxide-chloride system on the egg white lysozyme. Acta Biochim. Pol. 35:1988;277-286.
27. Heineke J.W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol. 8:1997;268-274.
28. Kisilevsky R. Inflammation-associated amyloidogenesis. Lessons for Alzheimer's amyloidogenesis. Mol. Neurobiol. 8:1993;65-66.
29. Jolivalt C., Leininger Muller B., Drozdz R., Naskalski J.W., Siest G. Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Neurosci. Lett. 210:1996;61-64.
30. Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J. Biol. Chem. 262:1987;14352-14360.
31. Janknecht R., de Martynoff G., Lou J., Hpiskind R.A., Nordheim A., Stunnenberg H.G. Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. Proc. Natl. Acad. Sci. USA. 88:1991;8972-8976.
32. Barbier A., Visvikis A., Mathieu F., Diez L., Havekes L., Siest G. Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli. Eur. J. Clin. Chem. Clin. Biochem. 35:1997;581-589.
33. Sigalov A., Alexandrovitch O., Strizevskaya E. Large-scale isolation and purification of human apolipoproteins A-I and A-II. J. Chromatogr. 537:1991;464-468.
34. Naskalski J.W. Simple procedure of isolation of myeloperoxidase from leukocytes, pus and bone marrow cells. Acta Med. Pol. 21:1980;129-137.
35. Zcliczynski J.M., Stelmaszynska T., Domanski J., Ostrowski W. Chloramines as intermediates of oxidation reaction of amino acids by myeloperoxidase. Biochim. Biophys. Acta. 235:1971;419-424.
36. Keller R.J., Halmes N.C., Hinson J.A., Pumford N.R. Immunochemical detection of oxidized proteins. Chem. Res. Toxicol. 6:1993;430-433.
37. Jonas A. A review of plasma apolipoprotein A-I interaction with phosphatidylcholines. Exp. Lung Res. 6:1984;255-270.
38. Zhuang Z., Huang X., Costa M. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. Toxicol. Appl. Pharmacol. 126:1994;319-325.
39. Davies K.J.A., Delsignore M.E. Protein damage and degradation by oxygen radicals. J. Biol. Chem. 262:1987;9908-9913.
40. Ladu M.J., Gilligan S.M., Kukens J.R., Gabana V.G., Reardon C.A., Van Eldik L.J., Holtzman D.M. Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70:1998;2070-2081.
41. Zorich N., Jonas A., Pownall H.J. Activation of lecithin cholesterol acyltransferase by human apolipoprotein E in discoidal complexes with lipids. J. Biol. Chem. 260:1985;8831-8837.
42. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
43. Heinecke J.W., Li W., Francis G.A., Golstein J.A. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J. Clin. Invest. 91:1993;2866-2872.
44. Anantharamaiah G.M., Hughes T.A., Iqbal M., Gawish A., Neame P.J., Medley M.F., Segrest J.P. Effect of oxidation on the properties of apolipoproteins AI and AII. J. Lipid Res. 29:1988;309-318.
45. Levine R.L., Mosoni L., Berlett B.S., Stadtman E.R. Methionine residues as endogenous antioxidants in proteins. Proc. Natl. Acad. Sci. USA. 93:1996;15036-15040.
46. Garner B., Waldeck A.R., Witting P.K., Rye K.A., Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 273:1998;6088-6095.
47. Dong L.M., Parkin S., Trakhanov S.D., Rupp B., Simmons T., Arnold K.S., Newhouse Y.M., Innerarity T.L., Weisgraber K.H. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat. Struct. Biol. 3:1996;718-722.
48. Droge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H.P., Roth S., Gmunder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 8:1994;1131-1138.
49. Grant A.J., Jessup W., Dean R.T. Inefficient degradation of oxidized regions of protein molecules. Free Radic. Res. Commun. 18:1993;259-267.
50. Wurtman R.J. Choline metabolism as a basis for selective vulnerability of cholinergique neurons. Trends Neurosci. 15:1992;117-122.
51. Terry R.D. Regeneration in Alzheimer disease and aging. Adv. Neurol. 59:1993;1-4.
52. Masliah E., Mallory M., Ge N., Alford M., Veinberg I., Roses A.D. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136:1995;107-122.
53. Reynolds W.F., Rhees J., Maciejewski D., Paladino T., Sieburg H., Maki R.A., Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp. Neurol. 155:1999;31-41.
54. Lyras L., Evans P.J., Shaw P.J., Ince P.G., Halliwell B. Oxidative damage and motor neurone disease difficulties in the measurement of protein carbonyls in human brain tissue. Free Radic. Res. Commun. 24:1996;397-406.
55. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69:1997;1326-1329.
56. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbuy P., Grewdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. 336:1997;1216-1222.
57. Le Bars, P. L.; Katz, M. M.; Berman, N.; Itil, T. M.; Freedman, A. M.; Schatzberg, A. F. A placebo-controlled, double-bind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278:1327-1332; 1997.